Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Development and assessment of a stiffness display system for minimally invasive surgery based on smart magneto-rheological elastomers.

Hooshiar A, Alkhalaf A, Dargahi J.

Mater Sci Eng C Mater Biol Appl. 2020 Mar;108:110409. doi: 10.1016/j.msec.2019.110409. Epub 2019 Nov 13.

PMID:
31924050
2.

Assessment of knowledge and attitude toward organ donation among the Saudi population in Riyadh City.

Alsharidah DS, Al-Dossari FS, AlMahmoud N, Alanzan BA, Binkhulaif RJ, Bakhsh EM, Alkhalaf AA, Bin Huzim BA, Sarhan NT, Sulayem LM, ElFeky DS, Syed S.

Saudi J Kidney Dis Transpl. 2018 Nov-Dec;29(6):1326-1332. doi: 10.4103/1319-2442.248304.

3.

The impact of WhatsApp use on academic achievement among Saudi medical students.

Alkhalaf AM, Tekian A, Park YS.

Med Teach. 2018 Sep;40(sup1):S10-S14. doi: 10.1080/0142159X.2018.1464652. Epub 2018 Jun 17.

PMID:
29909715
4.

Orthodontic Treatment Consideration in Diabetic Patients.

Almadih A, Al-Zayer M, Dabel S, Alkhalaf A, Al Mayyad A, Bardisi W, Alshammari S, Alsihati Z.

J Clin Med Res. 2018 Feb;10(2):77-81. doi: 10.14740/jocmr3285w. Epub 2017 Dec 30. Review.

5.

Association between Exposure to Ambient Air Particulates and Metabolic Syndrome Components in a Saudi Arabian Population.

Shamy M, Alghamdi M, Khoder MI, Mohorjy AM, Alkhatim AA, Alkhalaf AK, Brocato J, Chen LC, Thurston GD, Lim CC, Costa M.

Int J Environ Res Public Health. 2017 Dec 25;15(1). pii: E27. doi: 10.3390/ijerph15010027.

6.

Temporal variations of fine and coarse particulate matter sources in Jeddah, Saudi Arabia.

Lim CC, Thurston GD, Shamy M, Alghamdi M, Khoder M, Mohorjy AM, Alkhalaf AK, Brocato J, Chen LC, Costa M.

J Air Waste Manag Assoc. 2018 Feb;68(2):123-138. doi: 10.1080/10962247.2017.1344158. Epub 2018 Jan 16.

7.

Health risk associated with airborne particulate matter and its components in Jeddah, Saudi Arabia.

Harrison RM, Bousiotis D, Mohorjy AM, Alkhalaf AK, Shamy M, Alghamdi M, Khoder M, Costa M.

Sci Total Environ. 2017 Jul 15;590-591:531-539. doi: 10.1016/j.scitotenv.2017.02.216. Epub 2017 Mar 9.

PMID:
28285859
8.

Ingenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion.

Alkhalaf A, Hofbauer GF.

Dermatology. 2016;232 Suppl 1:17-9. doi: 10.1159/000447391. Epub 2016 Aug 11.

9.

Air quality in Yanbu, Saudi Arabia.

Khalil MA, Butenhoff CL, Porter WC, Almazroui M, Alkhalaf A, Al-Sahafi MS.

J Air Waste Manag Assoc. 2016 Apr;66(4):341-55. doi: 10.1080/10962247.2015.1129999.

PMID:
26671649
10.

Subcutaneous abatacept in rheumatoid arthritis: current update.

Keystone E, Alkhalaf A, Makkawy M.

Expert Opin Biol Ther. 2015;15(8):1221-30. doi: 10.1517/14712598.2015.1065248. Review.

PMID:
26160492
11.

Alanine aminotransferase and mortality in patients with type 2 diabetes (ZODIAC-38).

Deetman PE, Alkhalaf A, Landman GW, Groenier KH, Kootstra-Ros JE, Navis G, Bilo HJ, Kleefstra N, Bakker SJ.

Eur J Clin Invest. 2015 Aug;45(8):807-14. doi: 10.1111/eci.12474. Epub 2015 Jul 3.

PMID:
26046667
12.

A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.

Pena MJ, Heinzel A, Heinze G, Alkhalaf A, Bakker SJ, Nguyen TQ, Goldschmeding R, Bilo HJ, Perco P, Mayer B, de Zeeuw D, Lambers Heerspink HJ.

PLoS One. 2015 May 14;10(5):e0120995. doi: 10.1371/journal.pone.0120995. eCollection 2015.

13.

Comparison of methods for renal risk prediction in patients with type 2 diabetes (ZODIAC-36).

Riphagen IJ, Kleefstra N, Drion I, Alkhalaf A, van Diepen M, Cao Q, Groenier KH, Landman GW, Navis G, Bilo HJ, Bakker SJ.

PLoS One. 2015 Mar 16;10(3):e0120477. doi: 10.1371/journal.pone.0120477. eCollection 2015.

14.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. Epub 2015 Jan 14.

15.

Sex specific association between carnosinase gene CNDP1 and cardiovascular mortality in patients with type 2 diabetes (ZODIAC-22).

Alkhalaf A, Landman GW, van Hateren KJ, Groenier KH, Mooyaart AL, De Heer E, Gans RO, Navis GJ, Bakker SJ, Kleefstra N, Bilo HJ.

J Nephrol. 2015 Apr;28(2):201-7. doi: 10.1007/s40620-014-0096-6. Epub 2014 Apr 23.

PMID:
24756973
16.

Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28).

Gerrits EG, Alkhalaf A, Landman GW, van Hateren KJ, Groenier KH, Struck J, Schulte J, Gans RO, Bakker SJ, Kleefstra N, Bilo HJ.

PLoS One. 2014 Feb 25;9(2):e89719. doi: 10.1371/journal.pone.0089719. eCollection 2014.

17.

Health and well-being among physicians.

Alsuwaida A, AlSharidi A, AlAnazi N, AlGhamdi M, AlMeshal M, AlJaser R, AlAnazi R, Alkhalaf A.

Intern Med J. 2013 Dec;43(12):1310-5. doi: 10.1111/imj.12249.

PMID:
23869516
18.

Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31).

Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, van Hateren KJ, Struck J, Navis G, Bilo HJ, Bakker SJ.

Diabetes Care. 2013 Oct;36(10):3201-7. doi: 10.2337/dc12-2165. Epub 2013 Jun 11.

19.

Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT.

Diabetologia. 2013 Aug;56(8):1680-8. doi: 10.1007/s00125-013-2922-0. Epub 2013 Apr 28.

PMID:
23624546
20.

Beating and insulting children as a risk for adult cancer, cardiac disease and asthma.

Hyland ME, Alkhalaf AM, Whalley B.

J Behav Med. 2013 Dec;36(6):632-40. doi: 10.1007/s10865-012-9457-6. Epub 2012 Sep 29.

PMID:
23054177
21.

Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29).

Drion I, Kleefstra N, Landman GW, Alkhalaf A, Struck J, Groenier KH, Bakker SJ, Bilo HJ.

Diabetes Care. 2012 Nov;35(11):2354-8. doi: 10.2337/dc11-2526. Epub 2012 Jul 26.

22.

Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.

Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJ.

PLoS One. 2012;7(7):e40427. doi: 10.1371/journal.pone.0040427. Epub 2012 Jul 6.

23.

Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials.

Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ.

Int J Endocrinol. 2012;2012:456279. doi: 10.1155/2012/456279. Epub 2012 Jan 26.

24.

Chronic kidney disease and mortality risk among older patients with type 2 diabetes mellitus (ZODIAC-24).

Drion I, van Hateren KJ, Joosten H, Alkhalaf A, Groenier KH, Kleefstra N, Wetzels JF, Bilo HJ.

Age Ageing. 2012 May;41(3):345-50. doi: 10.1093/ageing/afs002. Epub 2012 Feb 6.

PMID:
22314695
25.

Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.

van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D, Gans RO, Struck J, Bilo HJ, Gansevoort RT, Bakker SJ.

Clin Chem. 2012 Jan;58(1):293-7. doi: 10.1373/clinchem.2011.166348. Epub 2011 Sep 26.

26.

Support for a protective effect of bilirubin on diabetic nephropathy in humans.

Zelle DM, Deetman N, Alkhalaf A, Navis G, Bakker SJL.

Kidney Int. 2011 Mar;79(6):686. doi: 10.1038/ki.2010.503. No abstract available.

27.

Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy.

Alkhalaf A, Zürbig P, Bakker SJ, Bilo HJ, Cerna M, Fischer C, Fuchs S, Janssen B, Medek K, Mischak H, Roob JM, Rossing K, Rossing P, Rychlík I, Sourij H, Tiran B, Winklhofer-Roob BM, Navis GJ; PREDICTIONS Group.

PLoS One. 2010 Oct 20;5(10):e13421. doi: 10.1371/journal.pone.0013421.

28.

A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus.

Alkhalaf A, Bakker SJ, Bilo HJ, Gans RO, Navis GJ, Postmus D, Forsblom C, Groop PH, Vionnet N, Hadjadj S, Marre M, Parving HH, Rossing P, Tarnow L.

Diabetologia. 2010 Dec;53(12):2562-8. doi: 10.1007/s00125-010-1863-0. Epub 2010 Aug 14.

29.

Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient.

Al-Qadheeb NS, Althawadi S, Alkhalaf A, Hosaini S, Alrajhi AA.

Ann Saudi Med. 2010 Sep-Oct;30(5):404-7. doi: 10.4103/0256-4947.67087.

30.

Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes?

Mijnhout GS, Alkhalaf A, Kleefstra N, Bilo HJ.

Neth J Med. 2010 Apr;68(4):158-62. Review.

31.

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.

Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ.

Diabetes Care. 2010 Jul;33(7):1598-601. doi: 10.2337/dc09-2241. Epub 2010 Apr 22.

32.

Thiamine in diabetic nephropathy: a novel treatment modality?

Alkhalaf A, Kleefstra N, Groenier KH, Bakker SJ, Navis GJ, Bilo HJ.

Diabetologia. 2009 Jun;52(6):1212-3; author reply 1214-6. doi: 10.1007/s00125-009-1326-7. Epub 2009 Mar 19. No abstract available.

PMID:
19296076
33.

Re: Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies.

Bakker SJ, Alkhalaf A, Tarnow L, Navis G.

Diabetes. 2008 Dec;57(12):e16; author reply e17. doi: 10.2337/db08-1120. No abstract available.

34.

Lack of antigenic relationships between avian pneumovirus and four avian paramyxoviruses.

Alkhalaf AN, Saif YM.

Avian Dis. 2003 Jan-Mar;47(1):175-9.

PMID:
12713174
35.

Pathogenicity, transmissibility, and tissue distribution of avian pneumovirus in turkey poults.

Alkhalaf AN, Ward LA, Dearth RN, Saif YM.

Avian Dis. 2002 Jul-Sep;46(3):650-9.

PMID:
12243529

Supplemental Content

Loading ...
Support Center